1, 3-disubstituted-4-(2-aminoethyl)-2-imidazolidinones



United States Patent 3,365,450 1,3-DlSUBSTlTUTED-4-(2-AMlN()ETHYL)-2- IMIDAZOLIDINONES Carl D. Lunsfor-tl, Richmond, and Albert 1). Cale, J13,

Eon Air, Van, assignors to A. H. Robins Company, Inc., Richmond, Va., a corporation of Virginia No Drawing. Original application Dec. 31, 1964, Ser. No. 422,570, new Patent No. 3,337,580, dated Aug. 22, 1967. Divided and this application Dec. 28, 1966, Ser. No. 605,199

15 Claims. (Cl. 260-247.2)

ABSTRACT GF THE DESCLGSURE 1,3 disubstituted 4 (2 aminoethyl) 2-imidazolidinones; useful as analeptics and hypotensives.

The present application is a division of Ser. No. 422,- 570, filed Dec. 31, 1964, now Patent No. 3,337,580.

The present invention relates to certain novel heterocyclic organic compounds which may be referred to as substituted Z-imidazolidinones, and is more particularly concerned with 1,3 disubstitutedl-(Z-aminoethyl) 2- imidazolidinones, compositions thereof, and methods of making and using the same.

The invention is especially concerned with novel imidazolidinone compounds having the formula:

CH2 o=0 R-OHCH2CH-NR (1) wherein R is selected from the group consisting of loweralkyl, lower-alkenyl, phenyllower-alkyl, cycloalkyl, and cycloalkenyl, wherein R is selected from the group consisting of phenyl, loWer-akylphenyl, di-lower-alkylphenyl, lower-alkoxyphenyl, holaphenyl, trifluoromethylphenyl, lower-alkylhalophenyl, lower-alkylmercaptophenyl, di-lower-alkylaminophenyl, and naphthyl, and wherein R is amino.

The compounds of the invention having the foregoing Formula I are generally characterized by important pharmacological activity, indicative of their use in counteracting certain physiological abnormalities in an animal body. The compounds are analeptics, hypotensives, or both. Certain compounds of the series are potent analeptics, stimulating respiration and antagonizing central nervous system depression and exhibiting a particular antagonism against barbiturate-induced depression or poisoning at dose levels considerably below that at which untoward side effects occur. While the degree and relative degree of their activities vary, all compounds tested exhibited analeptic activity, although, as stated, because of the relative degree of activity, some are preferred as hypotensives. The salts have special utility in that they are water-soluble and have an extended duration of activity.

The activity of the active agents of the present invention, as evidenced by tests in lower animals, is indicative of utility based on their valuable activity in human beings as well as in lower animals. Clinical evaluation in human beings has not been completed, however. It will be clearly understood that the distribution and marketing of any compound or composition falling within the scope of the present invention for use in human beings will of course have to be predicated upon prior approval of governmental agencies, such as the US. Federal Food and Drug Administration, which are responsible for and authorized to pass judgment on such questions.

It is accordingly an object of the present invention to provide new and useful 1,3-disubstituted-4-(Z-aminoethyl) 2 imidazolidinones, compositions thereof, and methods of making and using the same. Other objects of the invention will be apparent to one skilled in the art, and still other objects will become apparent hereinafter.

In the definition of symbols in the foregoing Formula I and where they appear elsewhere throughout this specification, the terms have the following significance.

The term lower-alkyl as used herein includes straight and branched chain radicals of up to eight carbon atoms inclusive and is exemplified by such groups as methyl, ethyl, propyl, isopropyl, tertiary butyl, amyl, isoamyl, hexyl, heptyl, octyl, and the like. Lower alkoxy has the formula O-loWer-alkyl. The term lower-alkenyl includes straight and branched chain radicals of two up to eight carbon atoms inclusive and is exemplified by such groups as vinyl, allyl, methallyl, 4-pentenyl, 3-hexenyl, and 3-methyl-3-heptenyl. The term cycloalkyl as used herein includes primarily cyclic alkyl radicals containing three up to nine carbon atoms inclusive and encompasses such groups as cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, methylcyclohexyl, propylcyclohexyl, ethylcyclopentyl, propylcyclopentyl, dimethylcyclohexyl, cycloheptyl, and cyclooctyl. The term cycloalkenyl as used herein includes cyclic alkenyl radicals containing up to nine carbon atoms inclusive and encompasses the named cycloalkyl radicals having one or more double bonds, including such usual radicals as 1- and Z-cyclohexenyl and 1- and 2-cyclopentenyl. Included in the term phenyllower-alkyl are groups such as benzyl, phenethyl, methylbenzyl, phenpropyl, and the like. As stated, the radical R in the foregoing Formula I is inclusive of such groups as lower-alkyl, cycloalkyl, cycloalkenyl, and phenyllower-alkyl, which groups are all preferably radicals of a solely hydrocarbon nature.

When halogen is referred to herein, preferably but not necessarily a halogen of atomic weight in excess of nineteen but not greater than eighty is employed. Of the halogens, chlorine is preferred.

Among the suitable amino radicals included within the symbol R" are primary, secondary and tertiary amino radicals, such as unsubstituted amino (NH loweralkyl-amino; di-lower-alkyl-amino; lower-alkenyl-amino; di-lower-alkenyl-amino; phenylamino; (hydroxy-loweralkyl)-amino; di-(hydroxy-lower-alkyl)-amino; loweralkyl-(hydroxy-lower-alkyl)-amino; basic saturated monocyclic heterocyclic radicals having up to a maximum of twelve carbon atoms, as exemplified by piperidino; loweralkyl-piperidino, e.g., 2-, 3-, or 4-lower-a1ky1-piperidino; di-lower-alkyl-piperidino; e.g., 2,4-, 2,6-, or 3,5-di-loweralkyl-piperidino; lower alkoxy piperidino; pyrrolidino; loWer-alkyl-pyrrolidino; di-lower-alkyl-pyrrolidino; loweralkoXy-pyrrolidino; morpholino; lower-alkyl-morpholino; di-lower-alkyl morpholino; lower alkoxy morpholino; thiomorpholino; loweralkyl thiomorpholino; di-loweralkyl-thiomorpholino; lower-alkoxy-thiomorpholino; piperazino; lower-alkyl-piperazino (e.g., C- or N -methylpiperazrno); di-C-(lower-alkyl)-piperazino; N (loweralkyl)-C-(loWer-alkyl)-piperazino; N (hydroxy lowera1kyl)-piperazino; N-(lower-aliphatic acyloxy) and (especially lower-alkanoyloxy lower-alkyl)-piperazino [e.g., N-(acetoxy-, isobutyro-xy-, or octanoyloxyethyl or propyl)- piperazino]; lower-alkoxy-piperazino; N'-lower-alkoxyloWer-alkylpiperazino, e.g., N'-ethoxyethylpiperazino; and lower-carbalkoxy-piperazino.

Included Within the scope of -N-(lower-alkanoyl) amino are the corresponding tertiary amino radicals designated -N-(lower-alkanoyl)-N lower alkylamino. The term carbamyl encompasses not only the primary amino-containing carbarnyl radicals, but also the corresponding N-phenyland N-(lower-alkyD-carbamyl and N,N-di-(lower-alkyD-carbamyl radicals as well as the corresponding N,N-diphenyllower alkyl, N,N monocyclic alkyl, and saturated heterocyclic carbamyl radicals, wherein the saturated monocyclic heterocyclic radical is asset forth under the definition of amino in the foregolng. The amino moiety of the carbamyl radical is additionally variable in accord with the definition of amino previously given.

Among the suitable substituted phenyl radicals are phenyl radicals substituted by any radical or radicals which are not reactive or otherwise interfering under the conditions of reaction, such as lower-alkoxy, lower-alkylmercapto, lower-alkyl, di-lower-alkyl-amino, trifluoromethyl, halo, and the like. The substituted-phenyl radicals have preferably no more than one to three substituents such as those given above and, furthermore, these substituents can be in various available positions of the phenyl nucleus and, when more than one substituent is present, can be the same or different and can be in various position combinations relative to each other. The lower-alkyl, lower-alkoxy, lower-alkylmercapto, and dilower-alkyl-amino substituents each have preferably from one to four carbon atoms which can be arranged as straight or branched chains. A total of nine carbon atoms in all ring substituents is the preferred maximum.

Since R" is amino, the compounds of Formula I may be converted to and are most conveniently employed in the form of non-toxic pharmaceutically acceptable acid addition or quaternary ammonium salts. Such salts also have improved water-solubility. Although the non-toxic salts are preferred, any salt may be prepared for use as a chemical intermediate, as in the preparation of another but non-toxic acid addition salt. The free basic compounds of Formula I may be conveniently converted to their quaternary ammonium or acid addition salts by reaction of the free base with the selected acid or acid ester, e.g., an alkyl, cycloalkyl, alkenyl, cycloalkenyl or aralkyl halide, sulfate, or sulfonate, preferably in the presence of an organic solvent inert to the reactants and reaction products under the conditions of the reaction. The acids which can be used to prepare the preferred non-toxic acid addition salts are those which produce, when combined with the free bases, salts the anions of which are relatively innocuous to the animal organism in therapeutic doses of the salts, so that beneficial physiological properties inherent in the free bases are not vitiated by side-effects ascribable to the anions.

Appropriate acid addition salts are those derived from mineral acids such as hydrochloric acid, hydrobromic acid, hydriodic acid, nitric acid, sulfuric acid, and phosphoric acid; and organic acids such as acetic acid, citric acid, lactic acid, fumaric acid, and tartaric acid. The preferred acid addition salt is the hydrochloride. The quaternary ammonium salts are obtained, e.g., by the addition of alkyl, cycloalkyl, alkenyl, cycloalkenyl, or aralkyl esters of inorganic acids or organic sulfonic acids, to the free base form of the selected tertiary amino compound. The alkyl, cycloalkyl, alkenyl, cyclo-alkenyl, or aralkyl esters so used include such compounds as methyl chloride, methyl bromide, methyl iodide, ethyl bromide, propyl chloride, allyl chloride, allyl bromide, dimethyl sulfate, methyl benzene-sulfonate, methyl p-toluene sulfonate, benzyl halides such as p-chlorobenzyl chloride and p-nitrobenzyl chloride, and the like.

The acid addition salts are prepared either by dissolving the free base in an aqueous solution containing the appropriate acid and isolat'mg the salt by evaporating the solution, or by reacting the free base and the selected acid in an organic solvent, in which case the salt ordinarily separates directly or can be conventionally recovered by concentration of the solution or the like. Conversely the free base may be obtained conventionally by neutralizing the acid addition salt with an appropriate base such as ammonia, ammonium hydroxide, sodium carbonate or the like, extracting the liberated base with a suitable solvent, illustratively ethyl acetate or benzene, drying the extract and evaporating to dryness or fractionally distilling, or in other conventional manner.

When there are two or more basic nitrogen atoms present in the compounds of the invention, poly-acid-addition salts may be obtained by employing the proper increased molar ratios of acid to the free base.

The following Chart I illustrates the process of the invention and shows the various procedures involved both in preparing the starting materials and the final products of the invention. In Chart I, all the symbols have the values previously assigned.

(R, R and B have values previously assigned) (X is hologen, preferably chlorine) (P is an alkyl or aryl group) Notes: a. Use of the sodium salt of II prepared with NaNH; improves y eld in the step. b. S0X2=sulfinyl halides, e.g., thionyl chloride. 0. heating facilitates this step.

The starting materials for the process of the present invention are the appropriately substituted 3-arninopyrroli dines, represented in Chart I by Formula IV. These materials (IV) may in turn be obtained from a l-substituted- 3-pyrrolidinol, shown as Formula II.

As illustrated in the chart, a 1-substituted-3-pyrrolidinol (II) is converted to a 1-substituted-3-haloor 3-alkylsulfonyloxylor 3-arylsulfonyloXy-pyrrolidine (III) by reaction with an agent such as thionyl chloride or bromide, or an alkylor aryl-sulfonyl halide, and allowing the thus-formed 3-halo or 3-sulfonyloxy-pyrrolidine to react with a primary amine to produce a compound of Formula IV, the starting material of the present invention.

As a general procedure for preparing the starting materials (IV), a suspension of sodarnide in an appropriate solvent, e.g., dry toluene, is placed in a suitable reaction vessel, such as a three-liter three-necked round-bottomed flask equipped with stirrer, reflux condenser, thermometer and dropping funnel. The dispersion is maintained at a suitable temperature, generally less than about 50 C., during the dropwise addition of a 1-substituted-3-pyrrolidinol to the reaction medium. A solution of an arylsulfonyl halide is then added to the reaction mixture while maintaining a reduced temperature, e.g., about 10 C. Arylsulfonyl halides such as p-toluenesulfonyl chloride and benzene-sulfonyl chloride in toluene solution may be employed in the formation of the desired sulfonates. Stirring of the reaction mixture is continued for an additional period, generally about two hours, while allowing the temperature to rise slowly to about 2030 C. The reaction mixture is then washed several times with cold water to remove any remaining unreacted reactants. The toluene extract containing the pyrrolidine-3-sulfonate is dried with a suitable drying agent such as calcium sulfate. After removal of the drying agent, the toluene may be removed by evaporation and the residual sulfonate allowed to react with a primary arylamine, which is preferably employed in excess. The arylamine is added to the sulfonate and the temperature raised to a level of about ISO-175 C. for an extended period, such as five to ten hours. The length of time and temperature required for the reaction are dependent upon the type of arylamine used in a particular preparation. On termination of the heating or reflux period, any unreacted arylamine may be removed under reduced pressure (as by Water aspirator vacuum) and the remaining concentrated residue may be neutralized with an acid such as cold dilute hydrochloric acid. The resulting aqueous solution of the salt, e.g., the hydrochloride, of the desired base may then be neutralized with a strong caustic solution (as for example 50% aqueous sodium hydroxide) to yield the free aminopyrrolidine base. The free base may be separated by extraction with ether and dried in the usual manner (i.e., with calcium sulfate). The product may be isolated and purified by distillation under reduced pressure. In some preparations, the free bases may be advantageously converted to their acid addition salts, e.g., the fumarate or cyclohexylsulfamate salt.

The following preparations are given by way of illustration only and are not to be construed as limiting.

PREPARATION l.l-METHYL-3-ANILINOPYR- ROLIDINE A dry toluene (1 liter) suspension of sodamide (2 moles) was placed in a 3-liter, 3-necked, round-bottomed flask equipped with a stirrer, reflux condenser, thermometer and dropping funnel. While maintaining the dispersion at a temperature of -40 C., 1-methyl-3-pyrrolidinol (2 moles) was added dropwise. On completing 6 the addition of the pyrrolidinol, the reaction mixture was stirred for two hours, gradually lowering the temperature to 10 C. A dry toluene (1 liter) solution of p-toluenesulfonyl chloride (2 moles) was added dropwise maintaining the temperature at less than 20 C. The reaction mixture was stirred for two hours at 20-30 C. and then washed with cold water (2x500 ml.). The toluene extract was dried over anhydrous calcium sulfate (Drierite). After removal of the drying agent, the toluene was removed by evaporation and the concentrated tosylate was allowed to react with aniline (4.4 moles, 10% excess). Reaction of the aniline with the tosylate [(1-methyl-3- pyrrolidyl)-p-toluenesulfonate] was effected by heating at 150 C. for two hours and then raising the temperature to reflux and heating for an aditional three hours. The excess unreacted aniline was removed under reduced pressure (water aspirator vacuum) and the remaining residue treated with a suflicient amount of cold dilute hydrochloric acid to effect solution. The acid solution was extracted several times with ethyl ether, cooled, and

made basic with aqueous sodium hydroxide. The free base was removed by extraction with ether. The ether extracts were washed with water and dried over Drierite (anhydrous calcium sulfate). The drying agent was removed by filtration and the ether removed under reduced pressure. The resultant residue was then distilled at reduced pressure, B.P. 124-126" C. at 4 mm. pressure. The product was obtained in 52% yield. The corresponding fumarate salt was obtained from dry isopropanol solvent, M.P. 143144 C.

Analysis.Calculated for C I-1 N 0 C, 61.63; H, 6.90; N, 9.58 (fumarate salt). Found: C, 61.58; H, 7.07; N, 9.47.

The following compounds (2 through 12) were prepared in a manner similar to that described in Preparation 1 employing the appropriately substituted pyrrolidinol as starting material. The eleven products were isolated and analyzed, some of their properties being listed in Table I, and analytical data being listed in Table II. Experimental conditions for each of the preparations were substantially the same, except where certain ring-substituted anilines were employed. In those cases, the reaction mixture was heated for longer periods of time (up to 10 hours) at temperatures ranging from 170 to 175 C.

TABLE 1.PREPARATIONS 2 THROUGH 12 UNHR N I R Arylaminopyrrolidine Boiling Preparation Point, Pressure Yield, Remarks No. C. (mm/Hg) Percent 2 CH 94 6 0.15 12 Fumarate 129-130" C.

3 C211 COH5 137-9 4 66 Fumarate 103-104 C.

4 our. 01-- 113-5 0. 05 2s 5 can oruo 128-30 0.15 as 0 our. OH3 192-3 25 Fumarate 150-1555 0.

7 OH(CH3)2 CnH -3 4 42 Fumnrate 132-134" C.

TABLE 1-Continued NHR \NJ/ R Arylaminopyrrolidine Boiling Preparation Point, Pressure Yield, Remarks N0. C. (mm/Hg) Percent s carom 102-0 01 40 Fumarate158-159C.

9 011mm Q- 1205 0.03 41 Fumarate 105-100 0.

l 01 CH1 10 C 135-8 0.05 01 Furnarate1961970.

11 Q-on, c n. 100-4 0.01 40 Fumarate139140.50.

12 our. 145-50 0. 05 46 Fumarate162-163C.

TABLE IL-ANALYTICAL DATA ON PREPARATIONS 2 THROUGH 12 Calculated Found Preparation Empirical N 0. Formula C H N O H N 2 CmI'ImClNnOt 55.13 5. 86 8. 57 54. 91 5. 60 8.39 3 CmHzgNiO 62. 72 7. 24 9.14 62. 38 7. 08 9.07 CHEM/1N 64. 13 7. 62 12. 47 64. 39 7. 43 12. 72 CmHmNzO 70. 87 9. 16 12. 72 70. 69 9. 13. 07 CHHMNZ 77. 01 10. 16 12. 83 77. 16 9. 94 12. 59 C11H24N204* 67. 73 7. 55 8. 74 63.03 7. 49 8. 76 C1sH20N204* 64. 65 7. 84 8. 38 64. 49 7. 83 8. 07 C HNCINZOR 58. (i1 6. 83 7. 60 58. 69 6. 65 7. 48 CH25NzO-1* 66. 64 7. 83 7. 77 66. 38 7. 62 7. 59 CzrHziN Or 68. 46 6. 57 7. 60 68. 6. 52 7. 60 C20H21N2O4' 67. 39 6. 79 7.86 67. 77 6. 80 8. 10

*Fumerate salts.

PREPARATION 13 .-1-PHENETHYL-3-ANILINO- PREPARATION 14. 1-ETHYL-3-(M-TRIFLUORO- PYRROLIDINE The same general method employed in the preparation of the tosylate in Preparation 1 was used in this preparation with one exception, the p-toluenesulfonyl chloride was replaced with benzenesulfonyl chloride (in a toluene solution). The resultant (1-phenethyl-3-pyrrolidyl)benzenesulfonate (0.11 mole) was mixed with aniline (0.40 mole) and the mixture heated with stirring for two hours at 150 C. and then at reflux for three additional hours. The excess unreacted for three additional hours. The excess unreacted aniline was then distilled at reduced pressure and the residue dissolved in dilute hydrochloric acid. The acidic solution was extracted with ether and then made basic with 25% aqueous sodium hydroxide. The free base which separated was extracted with ether and the ether extracts washed several times with cold water. The ethereal solution was dried over sodium sulfate. The ether was removed by evaporation and the residual oil distilled at reduced pressure, B.P. 173- 175 C. at 0.04 mm. pressure. The viscous oil crystallized on standing and melted at 52-53.5 C.; the product was isolated in 46% yield.

Analysis.-Calculated for C18H22N2: C, 81.16; H, 8.32; N, 10.52. Found: C, 80.86; H, 8.29; N, 10.62.

METHYLANILINO)PYRROLIDINE N CYCLO- HEXYLSULFAMATE Utilizing the procedure described in Preparation 13, (1-ethyl-3-pyrrolidyl)benzenesulfonate was heated and reacted with m-trifluoromethylaniline to produce l-ethyl- 3-(m-trifiuoromethylanilino)pyrrolidine in 23% yield. Preparation of the cyclohexylsulfamate salt was accomplished by neutralization of the free base with cyclo hexylsulfamic acid in isopropanol solvent. The product was precipitated by the addition of isooctane, MP. 116 C.

Analysis.Calculated for C H F N O S: C, 52.16; H, 6.91; N, 9.60. Found: C, 52.27; H, 7.04; N, 9.65.

PREPARATION l5 .-1-( l-CYCLOHEXENY L) -3- ANILINOPYRROLIDINE Using the method described in Preparation 13, [1-(1- clohexenyl) 3 pyrrolidyl]benzenesulfonate is prepared and reacted with aniline to produce l-(l-cyclohexenyl)-3-anilinopyrrolidine. The 2-cyclohexeny1 compound may be prepared similarly by using the appropriate Z-cyclohexnyl starting compound.

PREPARATION 16.-1-ALLYL-3-ANILINOPYR- ROLIDINE Using the method of Preparation 13, (l-allyl-3-pyrrolidyl)benzenesulfonate is prepared and reacted with aniline to form 1-allyl-3-anilinopyrrolidine.

PREPARATION l7.l-METHYL-3- Z-METHYL- MERCAPTOANILINO) PYRROLIDINE Using the method of Preparation 13, (1-methyl-3-pyrrolidyl)benzenesulfonate is prepared and reacted with Z-methylmercaptoaniline to form l-methyl-3-(2-methylmercapto anilino) pyrrolidine.

PREPARATION l 8 .l -METHYL-3 (4-DIMETHYL- AMINOANILINO) PYRROLIDINE Using the method of Preparation 13, (1-methyl-3-pyrrolidyl)benzenesulfonate is prepared and reacted with 4-dimethylaminoaniline to produce l-methyl-3-(4-dimethylaminoanilino)pyrrolidine.

In the same manner, numerous other l-substitutes-3- anilinopyrrolidines Within the scope of Formula IV are prepared.

Where the foregoing preparations produce a compound having a methyl or other lower-alkyl group, it is to be understood that compounds containing other lower-alkyl groups of straight or branched nature and containing up to eight carbon atoms inclusive, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, amyl, isoamyl, hexyl, heptyl, and octyl, are prepared in the same manner by substitution in the process of the appropriate different lower-alkyl starting material. Likewise, where chloro or other halogen atom is present, although chlorine is preferred, further halogen compounds including iodo, bromo, chloro, and fiuoro compounds are prepared starting from the appropriate halogenated starting material. Similarly, where methoxy or other loweralkoxy group is present, other lower-alkoxy groups containing various lower alkyl groups having up to eight carbon atoms inclusive are prepared in the same manner from the appropriate different lower-alkoxy starting material. Moreover, when one di-lower-alkylamino group, such as the dimethylamino group, is present in a compound, other di-loWer-alkylamino compounds are prepared in the same manner starting Only with the selected different di-lower-alkylamino compound. In the same manner, ortho and meta substituted compounds are produced instead of the para by utilizing the selected ortho or meta substituted starting compound, and vice versa. Similarly, other molecular changes are readily made.

As shown in Chart I, the general procedure for the preparation of the compounds of the invention involves several steps, preparation of a 4-beta-haloethyl derivative (VI) and subsequent replacement of the chlorine atom by amino. The appropriately substituted 3-aminopyrrolidine (IV) is first used as starting material, and is allowed to react with a carbonyl halide, as for example, phosgene or carbonyl bromide, which results in production of the resulting intermediate carbamylhalide (V), with spontaneous or nearly spontaneous rearrangement and cleavage of the pyrrolidine ring and formation of an imidazolidinone ring. Heating does facilitate the reaction but is not always essential.

A suitable general procedure for cariying out the process is as follows:

A solution of phosgene, or other carbonyl halide, such as carbonyl bromide, is placed in a suitable reaction vessel, e.g., a three-necked round-bottomed flask equipped with a stirrer, reflux condenser, thermometer and dropping funnel, employing a solvent which is inert under the reaction conditions. Suitable solvents are chloroform, methylene chloride, and the like. The reaction may be carried out at any suitable temperature and in any suitable manner. A preferred temperature range is about zero to 25 C. About five hundred milliliters of solvent per mole of phosgene provides a suitable solution. The

10 appropriate l-alkyl-3-arylaminopyrrolidine (IV) is added dropwise with stirring while maintaining the temperature within the desired range. The substituted-pyrrolidine reactant is used in a quantity which preferably is at least equimolar to the phosgene or other carbonyl halide used. However, it is preferred that an excess of phosgene, as for example about two molar equivalents, be used in order to improve the yield of the desired product. The temperature may be allowed to rise slowly to room temperature over a suitable period as, for example, about one to two hours, and the solution finally permitted to reflux for a suitable period, such as about four to forty-eight hours. Although the reaction may be carried out at room temperature, elevated temperatures may be advantageously used to shorten the reaction time. After a suitable reaction period, the reaction mixture is cooled to a suitable temperature as for example about zero to 10 C. and the product is separated and isolated in an appropriate man ner. The isolation step usually comprises washing the reaction mixture with aqueous mineral acid, aqueous alkali,

1 drying, and concentrating and crystallizing the residue from an appropriate solvent. To facilitate purification when a product is not crystalline, the residue may be distilled at reduced pressure. The resulting product is the 4-beta-haloethyl-l,3-disubstituted-2-imidazolidinone (VI).

Conversion of the halo-derivative (VI), prepared as in the step previously described, to a 4-beta-aminoethyl-1,3- disubstituted-Z-imidazolidinone (VII) may be carried out by allowing the halo-derivative (VI) to react with an amine, such as morpholine, dimethylamine, or diethylamine. Any suitable reaction procedure may be used. An excess of the amine is frequently employed.

In the case of relatively non-volatile amines such as morpholine, the halo-derivative is refluxed, usually with at least two molar equivalents of amine, until the reaction is substantially complete. The exact reaction time required may vary depending upon the particular amine used, but two hours is generally sufiicient for complete reaction. A solvent, e.g., ethanol, isopropanol, dioxane, ethylene glycol, or the like, may be used, but such solvent is not essential. The excess amine and solvent are removed on a steam bath under reduced pressure. The residue is isolated and the product purified in any appropriate conventional manner.

Reaction of the halo-derivative (V1) with an excess of a volatile amine, such as dimethylamine, may be conducted in a stainless steel reaction bomb employing a suitable reaction solvent, e.g., ethanol, isopropanol, dioxane, or the like. The reactants together with the solvent are sealed in the bomb and heated to a suitable temperature, as for example, about 75200 C. The reaction may occur at room temperature, but elevated temperatures are usually advantageously employed to shorten the reaction period. The length of the reaction time varies with the type of amine and the temperature range employed, two hours of heating at temperatures within the range of -150" C. usually being sufficient to complete the reaction. A longer heating period may frequently be used without any resultant harm to the product. The bomb is cooled and any excess amine and solvent are removed, as under reduced pressure on a steam-heated rotary evaporator. The residue may then be isolated and purified in the manner as described above.

The following examples are given by way of illustration only and are not to be construed as limiting.

The examples immediately following illustrate the preparation of starting 1,3-disubstituted-4-(Z-haloethyl)-2- imidazolidinones.

Example 1 .4- (Z-chl roethyl -methy l-3-pheny l-Z- imidazolidinone A solution of phosgene (0.88 mole) in chloroform (500 ml.) Was placed in a two-liter three-necked roundbottomed flask fitted with a stirrer, condenser, dropping funnel and thermometer, and cooled to 0 C. While stirring and maintaining the temperature at 10-15 C 1 1 1-methyl-3-anilinopyrrolidine (0.44 mole) was added -dropwise. On completing the addition of the substituted pyrrolidine, stirring was continued for two hours while :the temperature rose to 25-30" C. The temperature of the reaction mixture was then raised to reflux for a period 12 point 51-52 C.) and was obtained in 86% yield based on the starting pyrrolidine.

Analysis.-Calculated for C H ClN O: C, 60.37; H, 6.33; N, 11.74; Cl, 14.85. Found: C, 60.40; H, 6.44; N, 11.71; Cl, 14.76.

of twelve hours. The reaction mixture was cooled to 5 Example 1 4 2 l,,- ;h .1 ;h 3 h l 2 -05 C., and washed with hydrochloric acid (6 N, imidazolidinone 200 ml.). The chloroform layer was allowed to separate Utilizing the method of Example 1, and then washed several tunes with water. The chlorot d 1 f b 1 form extracts were dried over anhydrous sodium sulfate am n-opyno I l 1s-reac e Wlt a 50 upon 0 Car Ony 10 bromide (COlJr 1n chloroform to give 4-(2-bromofiltered, and the chloroform evaporated on a rotary ethyl) 1 methy1 3 phenyl z imidazolidinolm team eVaPPratOr moderate reduced Pressure- The The following Examples 2 through 11 were carried out isolated residue was purified by vacuum distillation under in the manner f Example 1 employing h appropriatdy 9 P The Z-imidalolidinone derivative substituted pyrrolidine as a starting material. The prodhibited a bolllng range of 186190 C. at 0.1 mm. Hg 10 ucts were isolated and some of their characteristics are pressure (recrystallized from isopropyl ether; melting listed in Table III.

TABLE III EXAMPLES 2 THROUGH 11 I ClCI-I2CH2 2-Irnidaz0lidinone Example B.P., Pressure M.P., Yield, Remarks Number C. (mm. H C. percent R-group Til-group 2 C1115 CaH; 195-200 0. 08 67-68 90 (3H3 3 Gil-I H3C-- 172-176 0.04 70 n 1.5447; pale yellow oil.

4 C211 (ll-Q 176-180 0.05 90 Yellow oil.

5 C2115 GHQ-@- 205-207 0.05 '87 Clear amber oil.

F30 6 C1115 152-157 0.06 73 Pale yellow viscous oil; 11 1.5181.

7 CH(CH z C6H 167-170 0. 02 67-69 43 (I311; 8 CII(CH )2 168-170 0.05 41 Pale yellow oil; in)" 1.5424.

Cl (3H 9 omens. 185-187 0. 00s 45 10 CaH CI-I2 C l-I 228-232 0. 2 41 11 CzHs 185-188 0.03 Pale yellow viscous oil.

ANALYTICAL DATA ON EXAMPLES 2 THROUGH 11 Calculated Found Example Empirical Formula Number 0 H N 01 C H N Cl CmHnClNzO 61. 77 6.78 11. 08 14.03 61. 93 6. 76 11. 01 CmHmClN O 64. 16 7. 54 9. 98 64. 43 7. 52 9. 77 C13l-I16ClzN O 54. 36 5. 62 9. 76 24. 69 54. 52 5. 42 9. 47 CmHwClNzOz 59. 46 6. 77 9. 91 12. 54 59. 51 6. 71 9. 69 CMIIlGC IFKNZO 52. 42 5. 03 8. 73 52. 42 5. 61 8. 62 C141L9C1N2O 63.03 7.18 10. F0 13. 29 63. 07 7.08 10. 66 0151'111C1N2O 64. 16 7. 54 9. 98 64. 75 7. 67 10. 07 C llzgClgNgO 67.14 6. 8. 89 22. 57. 33 6. 27 8. 67 (ll llmClN O 6Q. 67 6.021 8.00 11.26 6%. 70 ll. 03 0.16 UnllwClN t) 67.42 6.152 9. .25 11.71 68.10 6.33 9.46

Utilizing the process of Example 1 above, the following compounds are prepared from the stated starting materials:

4-(2-chloroethyl)-1-cyclohexyl-3 phenyl 2 imidazolidinone by reacting 1-cyclohexyl-3-anilinopyrollidine and phosgene.

4-(2-chloroethyl)-1-cyclohexenyl-3-phenyl-2 imidazolidinone by reacting 1-cyclohexenyl-3 anilinopyrrolidine and phosgene.

4-(2-chloroethyl)-1-allyl-3-phenyl 2 imidazolidinone by reacting 1-allyl-3-anilinopyrrolidine and phosgenc.

4-(2-chloroethyl) -l-methyl-3-(2 methylmercaptophenyl)-2-imidazolidinone by reacting 1-methyl-3-(2-methylmercaptoanilino)pyrrolidine with phosgene.

4-(2-chloroethyl)-l-methyl-3 (4 dimethylaminophenyl)-2-imidazolidinone by reacting l-methyl-3-(4-dimethyl aminoanilino)pyrrolidine with phosgene.

The 4-(2-aminoethyl)-2-imidazolidinone compounds of the invention are generally prepared by heating a solution of the selected 4-(2-haloethyl)-2-imidazolidinone and the selected amine in a suitable reaction solvent, e.g., ethanol, a higher boiling alcohol such as butanol, a hydrocarbon solvent such as toluene, or the amine itself may be the solvent in some cases. A reaction temperature from about room temperature to about 120 C. is employed, preferably 100 to 120 C., and a reaction period of about eight to twenty-four hours is usually adequate. Higher reaction temperatures increase the speed of reaction but tend to in crease the incidence of undesired side reactions, while temperatures below 100 C. frequently require undesirably lengthy reaction periods. Pressure to the extent generated in a sealed system is frequently employed to facilitate the reaction. The amine is usually employed in excess, at least two molar equivalents of the amine being preferred per each molar equivalent of starting halogen compound. The resulting solution of the amine reaction product is concentrated, as in vacuo, and the amine product isolated, usually as a crystalline hydrohalide salt. In most cases the hydrohalide salts, e.g., the hydrochloride, crystallize as the hydrate. In cases where a crystalline salt is diflicult or impossible to obtain, the free basic amine itself may be distilled and crystallized from a solvent or solvent mixture or alternatively isolated as an oil by fractional distillation. Extraction of the reaction product with a suitable solvent, e.g., ether, benzene, toluene, or ethyl acetate, frequently assists in recovering all of the available product for isolation by crystallization or the like and concentrated acid, e.g., 2 N HCl, or anhydrous ketones, e.g., methyl ethyl ketone, are frequently of value as the solvent or medium from which crystallization or recrystallization is effected.

Where the free base is desired, this may be obtained conventionally by neutralizing the reaction product or a solution of the isolated salt with a base such as ammonia, ammonium hydroxide, sodium carbonate, or other suitable alkaline material, extracting the liberated base with a suitable solvent such as ethyl acetate or benzene, drying the extract and evaporating to dryness in vacuo or fractionally distilling, or in other conventional manner. Numerous acid addition as well as quaternary ammonium (onium) salts may be prepared from the free bases, either isolated or without isolation from the reaction product, as already indicated in the foregoing. The amine preparation is illustrated by the following specific examples.

Example 12.4-(Z-pyrrolidinoethyl)-J-ethyl-3-(3-triflu0- romethylphenyl) -2-imidaz0lidine fumarate An excess of pyrrolidine (200 milliliters) was added to 4- (Z-chloroethyl) -1-ethyl-3- 3-trifluoromethylphenyl) 2- imidazolidinone (0.078 mole) and the mixture was refluxed for twelve hours. Excess pyrrolidine was removed under reduced pressure and the concentrate partitioned between ether and Water. The ether extracts were washed with water, dried over sodium sulfate and the ether removed by evaporation. The residual oil (free base; 80%

This compound was prepared in the manner of the preceding example except that morpholine was used instead of pyrrolidine. The morpholine hydrochloride was isolated from the initial reflux step by filtration from the ether extract leaving the desired free base in the ether filtrate. Removal of the ether by evaporation yielded the oily free base which was converted to the fumarate salt. Recrystallization of the furnarate salt from methyl ethyl ketone and isopropanol using a trace of ether gave the desired product, melting at 172173 C., in 92% yield.

AnaZysis.Calculated for C H F N O C, 54.20; H, 579; N, 8.62. Found: C, 54.00; H, 5.58; N, 8.73.

Example 14.-4-(2-m0rpholin0ethyl)-1-is0pr0pyl- 3-phenyZ-Z-imidazolidinone Morpholine (100 milliliters) was added to 4-(2-chloroethyl)-1-isopr0pyl-3 phenyl 2 imidazolidinone (0.585 mole) and the solution refluxed for two hours. Excess morpholine was removed on a steam bath under reduced pressure and the residue then dissolved in dilute aqueous hydrochloric acid (200 milliliters). The solution was washed with ether. The aqueous acid solution was made basic with sodium hydroxide and extracted with chloroform. The chloroform extract was dried over sodium sulfate and concentrated. The residue crystallized on standing; 94.5% yield. The product was recrystallized from isopropyl ether, melting point 88 C.

Analysis.--Calculated for C H N O C, 68.11; H, 8.58; N, 13.24. Found: C, 68.17; H, 8.49; N, 13.17.

Example 15.4-(2-m0rpholin0ethyl)-1-cycl0hexyl- 3-phenyZ-Z-imidazolidinone maleate An excess of morpholine (200 milliliters) was added to 4-(2-chloroethyl)-l cyclohexyl 3 phenyl-Z-imidazolidinone (0.16 mole) and the solution was refluxed for 48 hours. On cooling, the morpholine hydrochloride crystallized out and was removed by filtration. The remaining filtrate was concentrated on a rotary steam evaporator at reduced pressure. The concentrate was made acid with aqueous hydrochloric acid (6 N) and extracted with ether. The acid solution was then made basic with aqueous sodium hydroxide (6 N) and extracted with ether. The ether extract from the basic aqueous solution was dried and evaporated to yield an oil which was converted to the maleate salt from an isopropanol and isopropyl ether solvent system. The product melted at 141l42 C and was obtained in yield.

Analysis-Calculated for C H N O C, 63.40; H, 7.45; N, 8.87. Found: C, 63.64; H, 7.45; N, 8.93.

Example 16.-4- (Z-marpholinoezhyl) -1-benzyl-3-phenyl- Z-imidazolidinone An excess of morpholine (50 milliliters) was added to 4-(2-chloroethyl)-1-benzyl 3 phenyl-2-imidazolidinone (0.0635 mole) and the reaction solution was refluxed for four hours. The reaction solution was then cooled and concentrated in vacuo. The residue was dissolved in dilute aqueous hydrochloric acid and washed with isopropyl ether to remove any unreacted material. The aqueous acid layer was extracted with chloroform and the chloroform extract containing the hydrochloride was washed with dilute aqueous sodium hydroxide to form the free base, dried over sodium sulfate and concentrated in vacuo.

The product was recrystallized from 50% ethanol, melting point 119121 C.; 39% yield.

Analysis.Calculated for CzgHzqNgOzI C, 72.30; H, 7.45; N, 11.50. Found: C, 72.18; H, 7.58; N, 11.31.

Example 1 7.4-(2-dimetlzylaminoetlzyl) -1-ethyl-3- (4-methoxyplzenyl)-2-imidaz0lidinone hydrochloride A stainless steel bomb was charged with 4-(2-chloroethyl)-1-ethyl-3-(4-rnethoxyphenyl) 2 imidazolidinone (0.1 mole), absolute ethanol (100 milliliters) and dimethylamine (3.0 moles). The bomb was sealed and heated for 24 hours at 150 C. The reaction mixture was chilled and transferred to a flask where excess amine and ethanol were removed under reduced pressure. The residue was acidified, washed with ether, then basified with sodium hydroxide (6 N aqueous solution) and extracted with ether. The ether extracts were dried, the ether removed under reduced pressure and the residue (free base) vacuum distilled; boiling point 172177 C. at 0.008 mm. Hg pressure. The free base was converted to the hydrochloride salt by treatment of an isopropanol solution of the base with an ethereal solution of hydrochloric acid. The hydrochloric salt was recrystallized from isopropanolisopropyl ether solvent in 30% yield, melting point, 15 3- 153.5 C.

Analysis.Calculated for C H ClN O C, 58.61; H, 7.99; N, 12.82; Cl, 10.82. Found: C, 58.83; H, 8.15; N, 12.58; Cl, 10.73.

Example 18.4-(Z-dimet'hylaminoethyl) -1-etl1yl- 3-phenyZ-Z-imidazolidinone hydrochloride Utilizing the method of Example 31, 4-(2-chloroethyl)- 1-ethyl-3-phenyl-2-imidazolidinone is reacted with dimethylamine to give 4-(2-dimethylaminoethyl)-1-ethyl- 3-phenyl-2-imidazolidinone.

Example 19.-4-(2-diethylaminoethyl) -1-ethyl-3- (4-methoxyphenyl)-2-imidaz0lidinone fumarate The same procedure was employed as described in the preceding example except that diethylamine was used instead of dimethylamine. The free base was isolated by distillation under reduced pressure; boiling point 173- 180 C. at 0.0075 mm. Hg pressure. The free base was converted to the fumarate salt in isopropanol and crystallized on dilution with a small quantity of isopropyl ether in 28% yield, melting point 133-134 C.

Analysis.Calculated for C H N O C, 60.67; H, 7.64; N, 9.65. Found: C, 60.78; H, 7.77; N, 9.44.

Using the process described in Example 17, the following compounds are prepared from the stated starting materials:

4 (2-morph0lin0ethyl)-l-cyclohexyl-3-phenyl-2-imidazolidinone by reacting 4-(2-chloroethyl)-1-cyclohexyl-3- phenyl-2-imidazolidinone with morpholine.

4 (2 morpholinoethyl)-1-allyl-3-phenyl-2-imidaz0lidinone by reacting 4-(2-chloroethyl)-lallyl-3-phenyl-2- imidazolidinone with morpholine.

4 (2 dimethylaminoethyl)-1-ethyl-3-(4-methylphenyl) Z-imidazolidinone by reacting 4-(2-chloroethyl-1- ethyl-3-(4-methylphenyl)-2-imidazolidinone wtih dimethylamine.

4 (2 morpholinoethyl)-1-isopropyl-3-(2,4-dimethylpnenyl)-2-imidazolidinone by reacting 4-(2-chloroethyl)- 1 isopropyl 3-(2,4-dimethylphenyl)-2imidazolidinone with morpholine.

4 (2 morpholinoethyl) 1-isopropyl-3-(2-chlorophenyl)-2-imidazolidinone by reacting 4-(2-chloroethyl)- 1 isopropyl 3-(2-chlorophenyi)-2-imidazoiidinone with morpholine.

4 morpholinoethyl) 1-isopropyl-3-(4-chloro-2- methylphcnyl)-2-imidazolidinone by reacting 4-(2-chloroethyl) 1 isopropyl-3-(4-chloro-2-methylphenyl)-2-imidazolidinone with morpholine.

4 (2 diethylaminocthyl)-l-ethyl-3-(4-methyimercaptophenyl)-2-imidazolidinone by reacting 4-(2-chloroetn- 16 yl) 1 ethyl-3-(4-methylmercaptophenyl)-2-imidazolidinone with diethylamine.

4 (2 diethylaminoethyl)-1-ethyl-3-(4dimethylamin0- phenyl)-2-imidazolidinone by reacting 4-(2-chloroethyl)- 1 ethyl 3-(4-dimethylaminophenyl)-2-imidazolidinone with diet'nylamine.

Where the foregoing examples produce a compound having a methyl or other lower-alkyl group, it is to be understood that compounds containing other lower-alkyl groups of straight or branched nature and containing up to eight carbon atoms inclusive, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, amyl, isoamyl, hexyl, heptyl, and octyl, are prepared in the same manner by substitution in the process of the appropriate different lower-alkyl starting material. Likewise, where chloro or other halogen atom is present, although chlorine is preferred, further halogen compounds including iodo, bromo, chloro, and fiuoro compounds, are prepared starting from the appropriate halogenated starting material. Similarly, where methoxy or other lower-nlkoxy group is present, other lower-alkoxy groups containing various lower-alkyl groups having up to eight carbon atoms inclusive are prepared in the same manner from the appropriate different lower-alkoxy starting material. Moreover, when one dilower-alkylamino group, such as the dimethylamino group, is present in a compound, other diloWer-alkylamino compounds are prepared in the same manner starting only with the selected different dilower-alkylamino compound. in the same manner, ortho and meta products are produced instead of the para by utilizing the selected ortho or meta substituted starting material, and Vice versa. Similarly other molecular changes within the scope of the invention are readily made.

Formulation and administratiom-Etfectivc quantities of any of the foregoing pharmacologically active compounds may be administered to a living animal body in any one of various ways, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. The free basic amino compounds. While effective, are preferably formulated and administered in the form of their non-toxic acid-a ddition or quaternary ammonium salts for purposes of convenience of crystallization, increased solubility, and the like.

Although very small quantities of the active materials of the present invention, even as low as 0.1 milligram, are effective when minor therapy is involved or in cases of administration to subjects having a relatively low body Weight, unit dosages are usually five milligrams or above and preferably twenty-five, fifty or one-hundred milligrams or even higher, depending of course upon the emergency of the situation and the particular result, e.g., analeptic or hypotensive, desired. Five to fifty milligrams appears optimum per unit dose, while usual broader ranges appear to be one to milligrams per unit dose. The active agents of the invention may be combined with other pharmacologicaliy active agents, or with buffers, antacids or the like, for administration and the proportion of the active agent in the compositions may be varied Widely. It is only necessary that the active ingredient constitute an effective amount, i.e., such that a suitable effective dosage will be obtained consistent with the dosage form employed. Obviously, several unit dosage forms may be administered at about the same time. The exact individual dosages as well as daily dosages in a particular case will of course be determined according to established medical principles under the direction of a physician or veterinarian. Results upon administration of these novel materials have thus far proved extremely gratifying.

The formulations of Example 20 are representative for the pharmacologically active compounds of the invention, but have been especially designed to embody as active ingredient 1-loWer-alkyl-3-phcnyl 4 (bcta-aminoethyl) iinidazolio'inones, especially the dilower-alkylaminoethyl or hetero-cyclic aminocthyl compounds, or their hydro- 17 chlorides, hydrobromides, methiodides, or like pharmaceutically acceptable salts.

Example 20.Form-ulatins (1) CAPSULES Capsules of mg, 25 mg., and 50 mg. of active ingredient per capsule are prepared. With the higher amounts of active ingredient, reduction may be made in the amount of lactose.

Typical blend for encapsulation: Per capsule, mg.

Active ingredient, as salt 5.0 Lactose 296.7 Starch 129.0 Magnesium stearate 4.3.

Total 435.0

Additional capsule formulations preferably contain a higher dosage of active ingredient and are as follows:

Ingredients 100 mg. per 250 mg. per 500 mg. per

capsule capsule capsule Active ingredient, as salt 100. 0 250. 0 500. 0 Lactose 231. 5 126. 5 31. 1 Starch 99. 2 64. 2 l3. 4 Magnesium Stearate 4. 3 4. 3 5. 5

Total 435. O 435. 0 550. 0

In each case, uniformly blend the selected active ingredient with lactose, starch, and magnesium stearate and encapsulate the blend.

(2) TABLETS A typical formulation for a tablet containing 5.0 mg. of active ingredient per tablet follows. The formulation may be used for other strengths of active ingredient by adjustment of weight of dicalcium phosphate.

Per tablet, mg.

(1) Active ingredient 5.0 (2) Corn starch 13.6 (3) Corn starch (paste) 3.4 (4) Lactose 79.2 (5) Dicalcium phosphate 68.0 (6) Calcium stearate 0.9

Total 170.1

Uniformly blend 1, 2, 4 and 5. Prepare 3 as a 10 percent paste in water. Granulate the blend with starch paste and pass the wet mass through an eight mesh screen. The wet granulation is dried and seized through a twelve mesh screen. The dried granules are blended with the calcium stearate and compressed.

Additional tablet formulations preferably contain a higher dosage of the active ingredient and are as follows:

A. 50 MG. TABLET Ingredients: Per tablet, mg.

Active ingredient, as salt 50.0 Lactose 90.0 Milo starch 20.0 Corn starch 38.0 Calcium stearate 2.0

Total 200.0

Uniformly blend the active ingredient, lactose, milo starch and corn starch. This blend is granulated using water as a granulating medium. The wet granules are passed through an eight mseh screen and dried at 140 to 160 degrees Fahrenheit overnight. The dried granules are passed through a number ten mesh screen and blended with the proper amount of calcium stearate and this blend is then converted into tablets on a suitable tablet press.

B. MG. TABLET Ingredients: Per tablet, mg. Active ingredient, as salt 100.0 Lactose 190.0 Dicalcium phosphate 172.2 Starch 54.0 Milo starch 21.6 Calcium stearate 2.2

Total 540.0

Uniformly blend the active ingredient, lactose, dicalcium phosphate, starch and milo starch. This blend is granulated with water and the wet mass is passed through a number eight mesh screen. The wet granules are dried at degrees Fahrenheit overnight. The dried granules are passed through a number ten mesh screen. These dried granules are blended with the proper weight of calcium stearate and the lubricated granules are then converted into tablets on a suitable tablet press.

C. 250 MG. TABLET Ingredients: Per tablet, mg. Active ingredient, as salt 250.0

Corn starch -2 56.0 Carbowax 6000 (polyethylene glycol of M.W.

approximately 6000) 25.0 Lactose 35.0 Magnesium stearate 4.0

Total 370.0

Uniformly blend the active ingredient, corn starch, Carbowax 6000, lactose, and one-half the weight of magnesium stearate required. This blend is then slugged on a suitable tablet press. These slugs are granulated through a ten mesh screen on an oscillating granulator. These granules are then blended with the remainder of the magnesium stearate and the lubricated granules are then converted into tablets on a suitable tablet press.

D. 500 MG. TABLET Ingredients: Per tablet, mg. Active ingredient, as salt 500.0 Corn starch (wet) 86.4 Milo starch 32.4 Calcium stearate 3.2 Corn starch (dry) 26.0

Total 648.0

Uniformly blend the active ingredient, corn starch and milo starch. This blend is wet granulated using water and the wet mass is passed through a number eight mesh screen. These wet granules are dried overnight at 140-160 degrees Fahrenheit. The dried granules are passed through a number ten mesh screen. The dried granules and weighed amounts of corn starch and calcium stearate are uniformly blended and these lubricated granules are compressed on a suitable tablet press.

a INJECTABLE, 2% STERILE SOLUTION Per cc. Active ingredient 20 mg. Preservative, e.g., chlorobutanol 0.5% weight/volume. Water for injection, q.s.

present invent-ion without departing from the spirit or scope thereof, and it is therefore to be understood that the invention is to be limited only by the scope of the appended claims.

We claim:

1. A compound selected from the group consisting of (a) 4-(2-aminoethyl)-2-imidazolidinones having the formula:

is an amino radical selected from the group consisting of amino (-NH lower-alkyl-amino, di-loweralkyl-amino, lower-alkenyl-amino, di-lower-alkenylamino, phenylamino, (hydroxy-lower-alkyl)-amino, di- (hydroxy lower alkyl)-an1ino, lower-alkyl-(hydroxylower-alkyl)-amino, basic saturated monocyclic heterocyclic radicals having up to a maximum of twelve carbon atoms selected from the group consisting of piperidino, lower alkyl piperidino, di lower alkylpiperidino, lower-alkoxy-piperidino, pyrrolidino, loweralkyl pyrrolidino, di-lower alkyl pyrrolidino, loweralkoXy-pyrrolidino, morpholino, lower-alkyl-morpholino, di-lower-alkyl-morpholino, lower-alkoxy-morpholino, thiomorpholino, lower-alkyl-thiomorpholino, dilower-alkyl-thiomorpholino, lower-alkoxy-thiomorpholino, piperazino, lower-alkyl-piperazino, di-C-(loweralkyl) piperazino, N -(lower-alliyl)-C-(loweralkyl)- piperazino, N (hydroxy lower alkyl) piperazino, N (lower alkanoyloxy lower alkyl) piperazino, lower alkoxy piperazino, N lower alkoxy loweralkylpiperazino, lower carbalkoxy piperazino, N- lower-alkanoyl N lower alkylamino, and N loweralkanoylamino, and

(b) quaternary ammonium and acid-addition salts there- 2. A compound of claim 1 selected from the group consisting of 4-(2-dilower-alkylaminoethyl) -1-lower-alkyl- 3-phenyl-2-imidazolidinone and pharmaceutically acceptable acid addition and quaternary ammonium salts thereof.

3. A compound of claim 1 selected from the group consisting of 4 (2 morpholinoethyl) 1 lower alkyl- 3-phenyI-Z-imidazolidinone and pharmaceutically acceptable acid addition and quaternary ammonium salts thereof.

4;. A compound of claim 1 selected from the group consisting of 4 (2 dilower alkylaminoethyl) 1 lower-alkyl 3 lower-alkoxy-phcnyl-2-imidazolidinone and pharmaceutically acceptable acid addition and quaternary ammonium salts thereof.

5. A compound of claim 1 selected from the group consisting of 4 (2 morpholinoethyl) 1 lower alkyl- 3-trifluoromethylphenyl-2-imidazolidinone and pharmaceutically acceptable acid addition and quaternary ammonium salts thereof.

6. A compound of claim 1 selected from the group consisting of 4 (2 pyrrolidinoethyl) 1 lower alkyl- 3-trifiuorornethylphenyl-Z-imidazolidinone and pharmaceutically acceptable acid addition and quaternary ammonium salts thereof.

7. A compound of claim 1 which is a 4-(2-dimethylaminoethyl) 1 ethyl 3 phenyl 2 imidazolidinone pharmaceutically acceptable acid addition salt.

8. A compound of claim 1 which is a 4 (2 morpholinoethyl) 1 isopropyl 3 phenyl 2 imidazolidinone pharmaceutically acceptable acid addition salt.

9. A compound of claim 1 which is a 4 (2 morpholinoethyl) 1 cyclohexyl 3 phenyl 2 irnidazolidinone pharmaceutically acceptable acid addition salt.

It). A compound of claim 1 which is a 4 (2 morpholinoethyl) 1 benzyl 3 phenyl 2 imidazolidinone pharmaceutically acceptable acid addition salt.

11. A compound of claim 1 which is a 4 (2 morpholinoethyl) 1 ethyl 3 (3 trifluoromethylphenyl) 2- imidazolidinone pharmaceutically acceptable acid addition salt.

12. A compound of claim 1 which is a 4 (2 dimethylaminocthyl) l ethyl 3 (4 methoxyphenyl 2- imidazolidinone pharmaceutically acceptable acid addition salt.

13. A compound of claim 1 which is a 4 (2 diethylaminoethyl) 1 ethyl 3 (4 methoxyphenyl) 2- imidazolidinone pharmaceutically acceptable acid addition salt.

14. A compound of claim 1 which is a 4 (2 pyrrolidinoethyl) 1 ethyl 3 (3 trifluoromcthylphenyl)- 2 imidazolidinone pharmaceutically acceptable acid addition salt.

15. A compound of claim 1 which is selected from the group consisting of 4 (2 pyrrolidinoethyl) 1 ethyl- 3 (3 trifiuoromethylphenyl) 2 imidazolidinone fumurate, 4 (2 morpholinoethyl) 1 ethyl 3 (3- trifiuoromethylphenyl) 2 imidazolidinone fumurate, 4 (2 morpholinoethyl) 1 isopropyl 3 phenyl 2- imidazolidinone, 4 (2 morpholinoethyl) 1 cyclohexyl 3 phenyl 2 imidazolidinone maleate, 4 (2- morpholinoethyl) 1 benzyl 3 phenyl 2 imidazolidinone, 4 (2 dimethylaminoethyl) 1 ethyl 3- (4 methoxyphenyl) 2 imidazolidinone hydrochloride, 4 (2 dimethylaminoethyl) 1 ethyl 3 phenyl 2- imidazolidinone hydrochloride, and 4 (2 diethylaminoethyl) 1 ethyl 3 (4 methoxyphenyl) 2 imidazolidinone fumarate.

References Cited UNITED STATES PATENTS 3,196,152 7/1965 Wright et al. 260247.2

ALEX MAZEL, Primary Examiner.

', I. TOVAR, Assistant Examiner.

UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3,365,450 January 23, 1968 Carl D. Lunsford It is hereby certified that error appears in the above numbered patent requiring correction and that the said Letters Patent should read as corrected below.

Column 1, line 40, "holaphenyl" should read halophenyl Column 4, Chart I, Group (III), that portion of the formula reading C should read CH2 same column 4, same Chart I, Group (VII), that portion of the formula reading R -N-R should read R -ca CH2CH N-R' Column 8, line 71, "clohexenyl" should read cyclohexenyl Column 9, line 20, "l-substitutes" should read l-substituted Column 13, line 5, "anilinopyrollidine" should read anilinpyrrolidine Column 14, line 22, "579" should read 5.79 Column 15, line 23, "hydrochloric" should read hydrochloride line 32, "Example 31" should read--Example 16 line 59, "chloroethyll-" should read chloroethyl) -l- Column 17, line 52, "seized' should read sized line 71, "mseh" should read mesh Column 18, line 65, "Preparation" should read Prepare Signed and sealed this 19th day of August 1969.

(SEAL) Attest:

EDWARD M. FLETCHER,JR. WILLIAM E. SCHUYLER, JR.

Attesting Officer Commissioner of Patents 

